
GSK acquires Sierra Oncology for 1.9bn
GSK is paying $1.9 bn in cash ($55 per share) for the deal. This is a 39 per cent premium to the Sierra share price on 12 April and a 63 per cent...

From waste to sugar - demonstration plant opens in Wales
The project’s 11-strong European consortium secured €7m funding from Circular bio-based Europe JU (formerly Bio Based Industries Joint Undertaking)...

Switzerland shows sustained growth of biotech sector
Capital investments in Swiss biotech companies reached the second-best amount ever with CHF3.33bn in the second year of the pandemic, according to...

Vigeneron updates gene therapy collab with Daiichi Sankyo
Under the new agreement, Planegg-based AAV specialist ViGeneron GmbH will provide its novel engineered recombinant adeno-associated virus vectors...

Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Enzymaster raises $45m in Series C round
The Series C financing round was led by Yuanbio Venture Capital with While Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh...

Urovant Sciences cashes in $75m in licence deal from Pierre Fabre
Swiss Urovant Science, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., will receive up to USD $75m in upfront payment, regulatory, and sales...